• Alps Group entered a research and collaboration agreement with Kong Wai Mun, executive director of Axiocell Biotech, to launch an internal patient-derived organoid program.
• Move expands Alps into precision oncology testing, targeting personalized cancer treatment selection, preclinical drug screening, licensing services.
• Company aims to build Malaysia’s first clinically validated PDO platform, targeting MREC ethics approval, Medical Device Authority registration for commercialization.
• Plan includes a national PDO biobank, with initial clinical interest identified across six oncology centers in Malaysia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alps Group Inc. published the original content used to generate this news brief on June 23, 2026, and is solely responsible for the information contained therein.